



Building leadership in topicals for chronic inflammatory conditions

Dermatology Summit 2020

Jesper J. Lange, LLM
CEO

What matters most - the driver or the car?



A photograph of Lewis Hamilton, a Formula 1 driver, kneeling on the ground next to his silver Mercedes F1 car. He is wearing a white racing suit with teal and black accents, a colorful helmet, and white gloves. The car features prominent branding for Petronas, Mercedes, and other sponsors like Qualcomm and Epson. The number 44 is visible on the side of the car. A camera operator is partially visible on the right side of the frame.

Vehicle matters

A moment for man and machine after a
50th victory for Lewis in the Hybrid F1 era
Photo by Steve Etherington



PADTM

TECHNOLOGY

releasing the full potential

MC2 update: Positioned for transformation and growth

Mature private company

Commercial build-out in progress in US and EU to launch Wyzora™

Wyzora™ (psoriasis) on track

PDUFA date 20th July 2020 (US) – EU Ph3 successfully completed; MAA H1 2020


Transformative technology

PAD™ Technology is delivering on its promise to enable a new standard of topicals

Engineering BioMee™

A novel PAD™ based skin care line designed for dry and itchy skin - launch 2020


There is an unmet need for topicals that address all of three fundamentals:



Releasing full clinical potential in real life


PAD™ Technology is the solution to set a new standard for all stakeholders

Many topicals can be significantly upgraded



- Effect
- Tolerability
- Convenience

New molecules need better formulations



- Solubility
- Stability
- Delivery to target
- New patent life

Payers need better topicals to save costs



Annual patient cost
Biologics >\$30,000
Topicals ~ \$2,000

Patients need better treatment experience



Greasy Vaseline-like formulations


UPGRADE!



Non-greasy PAD™ creams – high convenience

The innovative solution

PAD™
TECHNOLOGY



Scanning electron microscopy image of PAD™ droplet



Wynzora™


US Ph3 data on Wynzora™ Cream for plaque psoriasis

Head-to-head US phase 3 trial against Taclonex® Topical Suspension

(0.005% w/w calcipotriene + 0.064% w/w betamethasone dipropionate cream)

Wynzora™ demonstrated significantly better efficacy compared to Taclonex® TS

Phase 3 (US): PGA Treatment Success variable



Wynzora™ Cream has very favorable safety profile - no adverse reaction exceeding 1%

No SAEs

No drug-related serious adverse events were observed in clinical trials

Few adverse reactions

Few adverse reactions substantiates attractive safety profile


All adverse reactions observed in US Ph 3 trial had a frequency < 1%

Mild adverse events


The majority of adverse events were mild and occurred at a frequency similar to vehicle

Wynzora™ Cream is more convenient to use than Taclonex® TS

Phase 3 (US): Secondary PRO: Patient treatment convenience scale




US market research¹



¹Triangle Insights research, n=11

Rx pipeline: Mature and targeting major chronic inflammatory conditions

Program	Active Ingredient	Indication	MC2 Rights	Pre-Clinical	Phase 2	Phase 3	Filing	Launch
Wynzora™ Cream	Calcipotriene /BDP	Psoriasis	Worldwide 2038	US			NDA Filed	PDUFA 20 July 2020
				EU			Ph3 completed	MAA H1-2020
MC2-03	Ciclosporin	Dry Eye	Worldwide 2032	Ph3 in planning				TBD
MC2-11	Tacrolimus	AD	Worldwide 2037					TBD
MC2-22	Crisaborole	AD	Worldwide 2038, FTO 27'					TBD
MC2-25	Undisclosed	Uremic Pruritus	Worldwide 2038					TBD



BioMee™

Launching BioMee™ in 2020 - a powerful skin care line for dry, itchy & sensitive skin



Anti-itch




Dry Skin



Barrier

- **Highly tolerable** – unique low amount of emulsifier <1%
- **Uniquely engineered** – for specific chronic conditions
- **New feel and experience** in daily routines

Our business goals are synergistic and enhances brand value of PAD™ Technology



Our “Stay Intact” strategy for transformation and growth is fully mapped out

Onboard attractive new opportunities

LONGER TERM ►

Building acquisition and licensing capabilities

- Onboard marketed drugs and/or late stage NCE's e.g. JAK, RoR G, TYK, IRAK and PDE-4
- Ideally suitable for an upgrade using PAD™ Technology

Commercialize & continue to build

ON-GOING ►

Commercial out-build

US & EU: Build commercial infrastructure
ROW: Out-license

PAD™ Rx Pipeline

- MC2-03 Ciclosp. (dry eye) Ph3 prep.
- MC2-25 Uremic Pruritus Ph2 prep.
- MC2-11 Tacrolimus (AD) Ph2 prep.
- MC2-22 Crisaborole (AD) Ph2 prep.

Leverage existing favorable position

EXISTING ►

Drugs

Wynzora™ Cream

US: PDUFA 20 July 20'
EU: MAA in H1 20'

PAD™
TECHNOLOGY

Pipeline generator

- Upgrade marketed Rx
- Enable NCE's
- LCM - New patents

BioMee™ (non-Rx)

- MC2-02 Anti-itch
- MC2-10 Sanitizer
- MC2-18 Barrier
- MC2-21 Dry skin

Experienced leadership and strong owners



PADTM

TECHNOLOGY

powerful & pure